Stories

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.

test

The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.

Zero Emission Day is a global initiative that raises awareness about the impact of human activities on climate change and promotes sustainable practices. 

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type…